/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Eledon Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.57 0.0743(7.43%) ELDN at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 1.485
Highest Today 1.61
Today’s Open 1.5
Prev. Close 1.48
52 Week High 5.08
52 Week Low 1.35
Day’s Range: Low 1.485 High 1.61
52-Week Range: Low 1.35 High 5.08
1 day return -
1 Week return -2.75
1 month return -61.77
3 month return -39.08
6 month return -47.52
1 year return -66.02
3 year return -33.75
5 year return -92.48
10 year return -

Institutional Holdings

Bvf Inc 10.51

RA Capital Management, LLC 5.96

Vanguard Group Inc 5.54

BlackRock Inc 5.43

First Light Asset Management, LLC 4.34

Sphera Funds Management Ltd. 3.27

Vanguard Total Stock Mkt Idx Inv 3.08

Woodline Partners LP 2.79

Geode Capital Management, LLC 2.31

iShares Russell 2000 ETF 2.31

Blue Owl Capital Holdings LP 2.22

Ensign Peak Advisors Inc 2.11

Nantahala Capital Management, LLC 1.91

Awm Investment Company Inc 1.84

Susquehanna International Group, LLP 1.70

Ikarian Capital, LLC 1.67

Schonfeld Strategic Advisors LLC 1.67

Zimmer Partners LP 1.64

Alyeska Investment Group, L.P. 1.56

Sanofi 1.36

Siren, L.L.C. 1.15

Vanguard Institutional Extnd Mkt Idx Tr 1.12

22NW, LP 1.06

Fidelity Small Cap Index 0.97

iShares Russell 2000 Value ETF 0.80

Fidelity Extended Market Index 0.54

MEDICAL BioHealth EUR Acc 0.49

Vanguard Russell 2000 ETF 0.47

State St Russell Sm Cap® Indx SL Cl I 0.35

Schwab Small Cap Index 0.25

NT R2000 Index Fund - NL 0.24

iShares Micro-Cap ETF 0.22

Extended Equity Market Fund K 0.20

Fidelity Total Market Index 0.19

NT R2000 Index Fund - DC - NL - 3 0.19

iShares Russell 2000 Small-Cap Idx Instl 0.17

Russell 2500™ Index Fund F 0.16

Fidelity Series Total Market Index 0.14

Nuveen Small Cap Blend Idx R6 0.13

Spartan Extended Market Index Pool F 0.12

Market Status

Strong Buy: 5

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 111.05 M

PB Ratio 3.2467

PE Ratio 0.0

Enterprise Value 22.12 M

Total Assets 177.41 M

Volume 927571

Company Financials

Annual Revenue FY24:null 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:120000 0.1M, FY20:120000 0.1M

Annual Profit FY24:-374000 -0.4M, FY23:null 0.0M, FY22:null 0.0M, FY21:120000 0.1M, FY20:120000 0.1M

Annual Net worth FY24:-40326000 -40.3M, FY23:-89084000 -89.1M, FY22:-87504000 -87.5M, FY21:-34506000 -34.5M, FY20:-22811000 -22.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:560000 0.6M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-97000 -0.1M

Quarterly Net worth Q3/2025:-17459000 -17.5M, Q2/2025:-11216000 -11.2M, Q1/2025:-6495000 -6.5M, Q3/2024:76971000 77.0M, Q2/2024:-44907000 -44.9M

Fund house & investment objective

Company Information Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Organisation Biotechnology

Employees 31

Industry Biotechnology

CEO Dr. David-Alexandre C. Gros M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow